Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ENCIDEX is an oral hygiene mouthwash developed and marketed by LAINCO. It is formulated as a combination of chlorhexidine digluconate (0.12%) and sodium fluoride (0.05%). It is indicated as an adjuvant in the treatment of periodontal diseases, such as gingivitis and periodontitis, and helps to reduce irritation, inflammation, and bleeding of the gums. Chlorhexidine digluconate acts as a broad-spectrum antiseptic and antimicrobial agent that disrupts bacterial cell walls and membranes, preventing plaque formation. Sodium fluoride acts as an anti-caries agent that interacts with hydroxyapatite in dental enamel to form acid-resistant fluorapatite, thereby strengthening teeth and promoting remineralization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlorhexidine digluconate + sodium fluoride.